2.1. Participants
Caucasian men (n = 59) and women (n = 33) aged 30 to 60 years (50.3±9.6 yrs., mean ± standard deviation [SD]) and affiliated to the cardiovascular (CV) lipid prevention clinic at the CHU de Québec-Université Laval (CHUL) were enrolled. These were patients treated with statins in primary CV prevention and with normal blood creatine kinase (CK) levels. Two statin groups were formed: a first self-reporting SAMS (SAMS, n = 61) and a second without SAMS (No SAMS, n = 15). A third group of participants not taking statins served as controls (Controls, n = 16). In this work, data are pooled from a pilot study and a main study (